Keurig Dr Pepper Stock Market Outlook
| KDP Stock | USD 29.22 0.69 2.42% |
When the sentiment score diverges from the price trend, it can highlight a disconnect between public perception and market action that merits a closer look. About 54% of recent sentiment around Keurig Dr has been mildly constructive over the recent sample. Taken on its own, that leaves Current sentiment reading for Keurig Dr Pepper close to neutral at this time.
Investor Comfort Level
Impartial
Panic | Confidence |
Maximum Pain Price Across 2026-06-18 Option Contracts
Keurig Dr Pepper max pain for the 2026-06-18 contracts is 32.00. Open interest around that strike level helps frame how options positioning may interact with price. The heaviest call open interest is 3 K contracts at the 30.00 strike, while put open interest peaks at 3 K contracts at the 24.00 strike. That balanced put-call skew provides context for how hedging activity may develop into expiration.
Elasticity to Hype and News Sentiment
Keurig Dr Pepper news coverage registers moderately positive at 70%, a data point that gauges whether public narrative is leading or lagging the business reality. Cross-checking that reading with earnings momentum and price action helps confirm whether the narrative is running ahead of or behind the business.
Over a 90-day investment horizon, with an above-average risk tolerance, the model output for Keurig Dr Pepper is 'Hold'. The Keurig Dr buy-or-sell recommendation is derived from the selected investment horizon and risk tolerance parameters for Keurig Dr.
Keurig |
Run Keurig Dr Outlook Model
Our model-driven Keurig signal adds context to the existing analyst consensus on Keurig Dr Pepper. Macroaxis maintains full independence and has no ownership position in Keurig Dr Pepper. Keurig Dr's outlook incorporates both technical signals and fundamental data points. Model-driven signals are most useful when they confirm or challenge existing views.
How This Model Works
The recommendation output for Keurig Dr is a model-based view that converts the selected horizon and risk profile into a standardized reading of the current evidence.
- Inputs - valuation signals, price behavior, volatility, liquidity, sentiment, and analyst coverage when available
- Current setup - Three Months with a risk setting described as I am an educated risk taker
- Limits - the model does not account for taxes, outside holdings, concentration constraints, or investor-specific mandates
Use the output as structured decision support and pair it with your own research, portfolio context, and any professional advice you rely on.
Time Horizon
Risk Tolerance
 | Hold |  |
Market Performance | Contained | Details | |
Volatility | Very Low | Details | |
Current Valuation | Below Model Estimate | Details | |
Odds Of Distress | Moderate | Details | |
Economic Sensitivity | Slowly supersedes the market | Details | |
Investor Sentiment | Impartial | Details | |
Analyst Consensus | Strong Buy | Details | |
Financial Strenth (F Score) | Strong | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
Keurig Dr's current outlook reflects a mixed setup, where recent market performance has undercut momentum, while volatility remains contained and operating conditions show early stabilization. The model's 'Hold' signal aligns with this balance, indicating limited near-term directional conviction despite pockets of underlying improvement. A Hold indicates that neither bullish nor bearish factors dominate, leaving the position without a clear directional edge. For the selected horizon, Keurig Dr yields Risk Adjusted Performance of 0.0623, Jensen Alpha of 0.1, and Total Risk Alpha of 0.1015, which produce a balanced but non-directional signal.The Keurig Dr buy-hold-or-sell recommendation draws on volatility, valuation, and earnings quality to produce a risk-aware signal that can be read alongside the analyst and expert consensus. To confirm fair pricing on this large-cap stock in the Consumer Defensive sector, confirm all 39 Keurig Dr fundamentals, including the relationship between the total debt and trailing beta. Keurig Dr Pepper reports a price to earnings of 30.21 X. Its market performance and financial distress probability provide additional context.
Recent Events and Market Context
The events below reflect recent headlines associated with Keurig Dr. Not all items directly affect the outlook — they are included to show the broader information environment that can shape sentiment and trading behavior.
Returns Distribution Density
The return distribution for Keurig Dr shows how Keurig Dr's daily price changes have varied. Returns near the center happen most often, while the edges show rare but large moves. Value At Risk pins down the downside, while Upside Potential pins down the upside. Combined with Value At Risk and Upside Potential, the expected performance range for Keurig Dr's is framed.
| Mean Return | 0.11 | Value At Risk | -2.63 | Potential Upside | 2.42 | Standard Deviation | 1.78 |
Return Density |
| Distribution |
The return distribution chart for Keurig Dr shows how often extreme price changes have occurred. The distribution of past returns provides that answer directly. It supports better-informed choices among risk-return profiles. Risk analysis for Keurig Dr begins with the return distribution chart.
Top Institutional Investors
Annual revenue is about 16.6 Billion. How Keurig Dr Pepper's institutional base reacts to earnings changes can move the stock in the short term. Shares outstanding are near 1.4 B. The small insider stake means governance incentives come more from pay packages than direct ownership.
| Shares | Barrow Hanley Mewhinney & Strauss Llc | 2025-12-31 | 21.2 M | Norges Bank | 2025-12-31 | 20.3 M | Amvescap Plc. | 2025-09-30 | 17.3 M | Capital Research & Mgmt Co - Division 3 | 2025-12-31 | 16.9 M | Ubs Group Ag | 2025-09-30 | 13.9 M | Allspring Global Investments Holdings, Llc | 2025-12-31 | 13.5 M | Northern Trust Corp | 2025-09-30 | 13.4 M | Aqr Capital Management Llc | 2025-12-31 | 11.6 M | Bank Of America Corp | 2025-09-30 | 10.7 M | Vanguard Group Inc | 2025-12-31 | 161 M | Fmr Inc | 2025-12-31 | 135.5 M |
Key Drivers of Volatility and Market Exposure
Holders of Keurig Dr face systematic risk from broad stock market trends and unsystematic risk from company or sector-specific developments. Diversification reduces specific exposure, but macro-driven volatility persists. Beta remains a common sensitivity metric. For Keurig Dr Pepper, recent data highlights a Downside Deviation of 1.54, a Mean Deviation of 1.25, and an Option Implied Volatility of 0.56.
α | Alpha over Dow Jones | 0.1 | |
β | Beta against Dow Jones | 0.37 | |
σ | Overall volatility | 1.82 | |
Ir | Information ratio | 0.06 |
Fundamentals Vs Peers
Keurig Dr's fundamentals are most informative when placed alongside stocks of comparable size and structure. This peer-level view determines whether Keurig Dr's current valuation multiple is justified by its relative operating performance. Fundamental peer comparison for Keurig Dr contextualizes operating performance within the competitive landscape. Mispricing opportunities for Keurig Dr become visible when key ratios diverge significantly from peer averages.
| Better Than Average | Worse Than Average | Compare Keurig Dr to competition |
| Fundamentals | Keurig Dr | Peer Average |
| Return On Equity | 0.0836 | -0.31 |
| Return On Asset | 0.0426 | -0.14 |
| Profit Margin | 0.13 | -1.27 |
| Operating Margin | 0.23 | -5.51 |
| Current Valuation | 63.62 B | 16.62 B |
| Shares Outstanding | 1.36 B | 571.82 M |
| Shares Owned By Insiders | 4.97 % | 10.09 % |
| Shares Owned By Institutions | 97.73 % | 39.21 % |
| Number Of Shares Shorted | 53.59 M | 4.71 M |
| Price To Earnings | 30.21 X | 28.72 X |
| Price To Book | 1.41 X | 9.51 X |
| Price To Sales | 2.34 X | 11.42 X |
| Revenue | 16.6 B | 9.43 B |
| Gross Profit | 9 B | 27.38 B |
| EBITDA | 4.19 B | 3.9 B |
| Net Income | 2.08 B | 570.98 M |
| Cash And Equivalents | 925 M | 2.7 B |
| Cash Per Share | 0.65 X | 5.01 X |
| Total Debt | 16.14 B | 5.32 B |
| Debt To Equity | 0.53 % | 48.70 % |
| Current Ratio | 0.60 X | 2.16 X |
| Book Value Per Share | 18.78 X | 1.93 K |
| Cash Flow From Operations | 1.99 B | 971.22 M |
| Short Ratio | 5.33 X | 4.00 X |
| Earnings Per Share | 1.53 X | 3.12 X |
| Price To Earnings To Growth | 0.89 X | 4.89 X |
| Target Price | 32.81 | N/A |
| Number Of Employees | 30.6 K | 18.84 K |
| Trailing Beta | 0.36 | -0.15 |
| Market Capitalization | 38.81 B | 19.03 B |
| Total Asset | 55.46 B | 29.47 B |
| Retained Earnings | 5.62 B | 9.33 B |
| Working Capital | -3.02 B | 1.48 B |
Note: Disposition of 6757 shares by Mary De Nooyer of Keurig Dr subject to Rule 16 b-3 [view details]
Market Momentum
With RSI at 65 and beta at 0.3693, Keurig Dr Pepper strength signals show whether demand and trading pressure are supporting or weakening the current setup. This combination is most actionable when validated against support-resistance levels and implied volatility trends.
Current Target Price Consensus
The consensus target for Keurig is calculated by averaging every analyst projection we track. The only reliable way to assess analyst accuracy is through backward-looking attribution analysis. The Keurig Dr projections below serve as one component of a broader analytical framework. Treating Keurig Dr's target price as one input among several produces a more reliable conclusion.
| 21 | Strong Buy |
Quarterly rating updates are standard for most Keurig analysts. Target prices frame Keurig Dr Pepper's current trading price against the analyst's view of the stock's worth. Ratings reflect thorough research into Keurig Dr Pepper's financial reports and management presentations. The institutional-quality research underlying each Keurig rating update extends the analysis beyond headline numbers.
Exposure ValuationKeurig Dr Target Price Projection
Keurig Dr's stock currently trades at 29.22 against an analyst consensus target of 32.81. While the market price of Keurig Dr Pepper reflects supply and demand, the target embodies analysts' forward-looking estimate. Larger discrepancies between these two values tend to attract more investor attention. Investors monitoring this spread over time can identify shifts in the market's view of Keurig Dr Pepper value.Target Price
Analyst Consensus On Keurig Dr Target Price
Keurig Dr Analyst Ratings
Wall Street is mostly bullish on Keurig Dr, with 21 analysts rating it Strong Buy. 14 analysts are positive, 7 are neutral, and 0 are negative. Neutral holds account for 7 of the 21 ratings on Keurig Dr. The historical pattern of these ratings follows in the chart.Analyst Consensus Breakdown
Average Consensus Estimates
Recommendation Framework, Assumptions & Editorial Oversight
The model output for Keurig Dr reflects the current horizon and risk settings, refreshes as underlying data changes, and is intended to organize evidence rather than replace investor judgment. Current model inputs for Keurig Dr include P/E of 30.21, ROE of 8.36%. External analyst coverage is currently summarized as Strong Buy across 21 analysts, but it is treated here as a secondary reference input rather than a stand-alone recommendation. Published target-price assumptions may also be reviewed when available, but they can change quickly as analyst models are revised. 
Keurig Dr Pepper metrics are compiled from periodic company reporting and market reference feeds and normalized before display. External analyst coverage may be referenced as a secondary input when available. The recommendation framework translates the selected risk tolerance and time horizon into a standardized model view using valuation, price behavior, volatility, liquidity, sentiment, and analyst coverage where available. It is informational rather than personalized and does not account for taxes, outside holdings, concentration limits, or investor-specific mandates.
Editorial Review & Methodology Oversight
Role: Macroaxis Contributor
Finance background: Vlad covers stocks, funds, cryptocurrencies, and ETFs that are traded in North America, focusing primarily on fundamentals, valuation and market volatility. He has many years of experience in fintech, predictive investment analytics, and risk management.
Oversight scope: Reviews recommendation-framework framing, source assumptions, and disclosure language.